Skip to content

Suspicious politician pharma stock trade is now up 111%

Suspicious politician pharma stock trade is now up 111%
Ana Zirojevic

As stock trades by politicians in the United States continue to draw attention due to the perceived unfair advantage they might have through their position, a pharmaceutical stock purchased by Representative Josh Gottheimer has gained an impressive 111% to its price since his trade.

Specifically, Gottheimer bought the stock of Agios Pharmaceuticals (NASDAQ: AGIO) earlier this year, on January 24, 2024, and it has since risen 111%, according to the data shared by Quiver Quantitative, the platform tracking politicians’ stock trades, in an X post on August 20.

AGIO stock price performance since Rep. Gottheimer’s purchase. Source: Quiver Quantitative
AGIO stock price performance since Rep. Gottheimer’s purchase. Source: Quiver Quantitative

As a reminder, he purchased between $1,001 and $15,000 worth of shares in the pharma company, which specializes in therapies for genetically defined diseases, with a near-term focus on developing treatments for hemolytic anemias, at an average price of $21.51.

Interestingly, as Quiver Quantitative noted in the original report, Gottheimer sits on the House Financial Services Committee, including the Subcommittee on Investor Protection, Entrepreneurship, and Capital Markets, as well as on the Select Intelligence Committee, which might provide him with insider knowledge.

At the same time, he has attracted attention for some of his various other stock trades, including the purchase of Fair Isaac (NYSE: FICO) stocks in April, buying Broadcom (NASDAQ: AVGO) shares in June, that of Northrop Grumman (NYSE: NOC) in July, and many other buys and sales.

Agios Pharmaceuticals stock price analysis

Meanwhile, the price of AGIO stocks at press time stood at $44.87, reflecting a 1.32% drop on the day, an increase of 0.23% across the week, declining 6.03% on the month but advancing 96.54% since the year’s turn, according to the latest chart data on August 21.

Agios Pharmaceuticals stock price year-to-date (YTD) chart. Source: Google Finance
Agios Pharmaceuticals stock price year-to-date (YTD) chart. Source: Google Finance

All things considered, Gottheimer is an active stock trader despite growing questions regarding ethical (and legal) aspects of such practices by U.S. politicians. That said, it is critical to do one’s own research and not blindly mimic anyone’s stock trades regardless of potential insider knowledge, as trends in the stock market can easily change.

Buy stocks now with eToro – trusted and advanced investment platform


Disclaimer: The content on this site should not be considered investment advice. Investing is speculative. When investing, your capital is at risk.

Best Crypto Exchange for Intermediate Traders and Investors

  • Invest in 70+ cryptocurrencies and 3,000+ other assets including stocks and precious metals.

  • 0% commission on stocks - buy in bulk or just a fraction from as little as $10. Other fees apply. For more information, visit etoro.com/trading/fees.

  • Copy top-performing traders in real time, automatically.

  • eToro USA is registered with FINRA for securities trading.

30+ million Users
Securities trading offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. Finbold.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD

Read Next:

Finance Digest

By subscribing you agree with Finbold T&C’s & Privacy Policy

Related posts

Sign Up

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

Already have an account? Sign In

Disclaimer: The information on this website is for general informational and educational purposes only and does not constitute financial, legal, tax, or investment advice. This site does not make any financial promotions, and all content is strictly informational. By using this site, you agree to our full disclaimer and terms of use. For more information, please read our complete Global Disclaimer.